| Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma W Hugo, JM Zaretsky, L Sun, C Song, BH Moreno, S Hu-Lieskovan, ... Cell 165 (1), 35-44, 2016 | 3146 | 2016 |
| Mutations associated with acquired resistance to PD-1 blockade in melanoma JM Zaretsky, A Garcia-Diaz, DS Shin, H Escuin-Ordinas, W Hugo, ... New England Journal of Medicine 375 (9), 819-829, 2016 | 3067 | 2016 |
| Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression A Garcia-Diaz, DS Shin, BH Moreno, J Saco, H Escuin-Ordinas, ... Cell Reports 19 (6), 1189-1201, 2017 | 1730 | 2017 |
| Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma TF Cloughesy, AY Mochizuki, JR Orpilla, W Hugo, AH Lee, TB Davidson, ... Nature medicine 25 (3), 477, 2019 | 1196 | 2019 |
| Primary resistance to PD-1 blockade mediated by JAK1/2 mutations DS Shin, JM Zaretsky, H Escuin-Ordinas, A Garcia-Diaz, S Hu-Lieskovan, ... Cancer discovery 7 (2), 188-201, 2017 | 1196 | 2017 |
| Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy H Shi, W Hugo, X Kong, A Hong, RC Koya, G Moriceau, T Chodon, R Guo, ... Cancer discovery 4 (1), 80-93, 2014 | 1079 | 2014 |
| Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma J Müller, O Krijgsman, J Tsoi, L Robert, W Hugo, C Song, X Kong, ... Nature communications 5, 5712, 2014 | 723 | 2014 |
| Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance W Hugo, H Shi, L Sun, M Piva, C Song, X Kong, G Moriceau, A Hong, ... Cell 162 (6), 1271-1285, 2015 | 628 | 2015 |
| Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction G Moriceau, W Hugo, A Hong, H Shi, X Kong, CY Clarissa, RC Koya, ... Cancer cell 27 (2), 240-256, 2015 | 382 | 2015 |
| Regional Glutamine Deficiency in Tumours Promotes De-differentiation through Inhibition of Histone Demethylation M Pan, MA Reid, XH Lowman, RP Kulkarni, TQ Tran, X Liu, Y Yang, ... Nature cell biology 18 (10), 1090, 2016 | 348 | 2016 |
| Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms DB Johnson, AM Menzies, L Zimmer, Z Eroglu, F Ye, S Zhao, H Rizos, ... European Journal of Cancer 51 (18), 2792-2799, 2015 | 346 | 2015 |
| Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis TJ Parmenter, M Kleinschmidt, KM Kinross, ST Bond, J Li, MR Kaadige, ... Cancer discovery 4 (4), 423-433, 2014 | 299 | 2014 |
| Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 2017; 7: 188–201. doi: 10.1158/2159-8290 DS Shin, JM Zaretsky, H Escuin-Ordinas, A Garcia-Diaz, S Hu-Lieskovan, ... CD-16-1223.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 248 | |
| A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition H Shi, A Hong, X Kong, RC Koya, C Song, G Moriceau, W Hugo, ... Cancer discovery 4 (1), 69-79, 2014 | 191 | 2014 |
| Recurrent tumor cell-intrinsic and-extrinsic alterations during MAPKi-induced melanoma regression and early adaptation C Song, M Piva, L Sun, A Hong, G Moriceau, X Kong, H Zhang, S Lomeli, ... Cancer Discovery, CD-17-0401, 2017 | 157 | 2017 |
| Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma A Lee, L Sun, A Mochizuki, J Reynoso, J Orpilla, F Chow, J Kienzler, ... | 151 | 2021 |
| Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma A Hong, G Moriceau, L Sun, S Lomeli, M Piva, R Damoiseaux, SL Holmen, ... Cancer Discovery 8 (1), 74-93, 2018 | 111 | 2018 |
| Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy E Pérez-Guijarro, HH Yang, RE Araya, R El Meskini, HT Michael, ... Nature Medicine 26 (5), 781-791, 2020 | 100 | 2020 |
| Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors AA Marusiak, ZC Edwards, W Hugo, EW Trotter, MR Girotti, ... Nature communications 5, 2014 | 90 | 2014 |
| JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma B Titz, A Lomova, A Le, W Hugo, X Kong, J Ten Hoeve, M Friedman, H Shi, ... Cell Discovery 2, 16028, 2016 | 68 | 2016 |
Antoni RibasUCLAVerified email at mednet.ucla.edu
